IL-11

Study confirms the novelty and atomic-level precision of de novo antibody design, including cryo-EM validation on a designed anti-PD-L1 antibody Findings highlight broad therapeutic applicability across oncology, immune, and metabolic diseases SEOUL, South Korea, Sept. 22, 2025 /PRNewswire/ -- Galux, a South Korea–based biotech company pioneering AI-driven protein therapeutics design, today announced new results that further validate its de novo antibody design platform, GaluxDesign. The findings showcase the platform's ability to generate novel antibodies that meet precise structural and functional requirements with atomic-level precision across a broad range of targets. Continue Reading Comparing designed structure and experimentally resolved structure(interface RMSD 1.1 Å) In March, Galux announced antibody designs for six therapeutic targets, at that time one of the most comprehensive demonstrations of de novo antibody design. Those antibodies showed binding affinity, thermal stability, and developability comparable to marketed antibodies, including designs for targets without known structural information. The new study extends this work to two additional targets, CD98hc and IL-11, bringing the total to eight: PD-L1, HER2, EGFR(S468R mutant), ACVR2A/B, FZD7, ALK7, CD98hc, and IL-11. Notably, IL-11 represents a target without any known antibody complex structure, highlighting the platform's capacity to tackle previously unexplored targets. For a designed antibody against PD-L1, Galux experimentally determined the antibody–antigen complex using cryo-EM. The designed antibody, GX-aPDL1-3, was highly distinct from all known PD-L1 antibodies in the PDB , sharing at most 43% sequence identity in CDR loops and only 27% in the critical H3 loop. Despite this novelty, the designed structure closely matched the experimentally resolved structures, with an interface RMSD of 1.1 Å, demonstrating atomic-level precision. The antibodies were initially validated in scFv format and subsequently characterized in IgG format, where favorable stability and binding properties were confirmed. Biophysical analyses across five targets reinforced the robustness of the designs. Notably, subtype- and mutant-specificity observed in scFv was preserved in IgG for antibodies targeting FZD7 and EGFR-S468R, while IL-11 binders successfully targeted multiple biologically meaningful epitopes as intended, demonstrating that binding properties can be rationally tuned. Beyond the technical achievement of de novo antibody design, the diversity of targets underscores the platform's potential applicability across therapeutic areas. The eight proteins are linked to oncology, fibrosis, metabolic disorders, and immune diseases, suggesting opportunities to address a wide range of therapeutics, including those difficult to target with conventional approaches. "Our findings indicate that antibodies designed entirely in silico can achieve both novelty and atomic-level precision," said Chaok Seok, CEO of Galux. "We believe this approach can expand the possibilities across diverse disease areas, opening new opportunities for precision molecular design that maximizes efficacy and minimizes toxicity, crucial for successful later-stage development." Galux is advancing its platform to address previously undruggable targets. The company is also in discussions with global pharmaceutical partners to explore collaborative opportunities. "We believe this is only the beginning," Seok added. "Our vision is to build a future where medicines are no longer discovered by chance, but rationally and precisely designed: faster, more efficiently, and for patients who need them the most around the world." The full paper is available here: SOURCE Galux WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

SHANGHAI, China and SOUTH SAN FRANCISCO, CA, USA I June 26, 2025 I Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SH), an innovative biopharmaceutical company, and Calico Life Sciences LLC (Calico) a biotechnology organization focused on aging and age-related diseases and founded by Alphabet Inc. and Arthur D. Levinson, Ph.D., today announced an exclusive licensing agreement for IL-11 directed therapeutics, including 9MW3811, a Phase I monoclonal antibody (mAb). Preclinically, Mabwell has explored the therapeutic potential of 9MW3811 in age-related diseases and has conducted Phase I trials in China and Australia. 9MW3811 also has an open IND to perform a U.S. Phase I trial. Under the terms of the agreement, Mabwell will grant Calico exclusive rights to develop, manufacture, and commercialize 9MW3811 in all regions except Greater China. About Mabwell Mabwell (688062.SH) is an innovation-driven biopharmaceutical company with the entire value chain of the pharmaceutical industry. The company provides more effective and accessible therapy and innovative medicines to fulfill global medical needs, focusing on oncology and aging-related disease indications. Mabwell’s mission is “Explore Life, Benefit Health” and its vision is “Innovation, from ideas to reality”. For more information, please visit www.mabwell.com/en. About Calico Calico (Calico Life Sciences LLC) is an Alphabet-founded research and development company whose mission is to harness advanced technologies and model systems to increase our understanding of the biology that controls human aging. Calico will use that knowledge to devise interventions that enable people to lead longer and healthier lives. To learn more about Calico, visit www.calicolabs.com . SOURCE: Mabwell

Calico Life Sciences announced a licensing deal with Mabwell Biosciences on Thursday for IL-11 directed therapeutics, including the Chinese firm's clinical asset. The ageing-focused biotech will receive exclusive, global rights to 9MW3811, an anti–IL-11 antibody, outside of China. Financial terms of the tie-up were not disclosed. According to Mabwell, it has explored the potential of 9MW3811 in preclinical studies for age-related diseases. The company has also run Phase I trials in China and Australia evaluating the antibody for idiopathic pulmonary fibrosis (IPF).At least two other companies have an IL-11 programme in development for IPF. Boehringer Ingelheim launched a Phase I study of BI 765423 in 2023 with partner Enleofen Bio, and Lassen Therapeutics is testing its LASN01 in patients with thyroid eye disease as well as IPF.Calico could move 9MW3811 quickly into the clinic, as the candidate has an open investigational new drug (IND) application for a US Phase I trial.